Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain.
about
A chimeric human immunodeficiency virus type 1 (HIV-1) minimal Rev response element-ribozyme molecule exhibits dual antiviral function and inhibits cell-cell transmission of HIV-1Decoy approach using RNA-DNA chimera oligonucleotides to inhibit the regulatory function of human immunodeficiency virus type 1 Rev proteinAnalysis of the EIAV Rev-responsive element (RRE) reveals a conserved RNA motif required for high affinity Rev binding in both HIV-1 and EIAVPolyvalent Rev decoys act as artificial Rev-responsive elements.Gene therapy for infectious diseasesFusion with an RNA binding domain to confer target RNA specificity to an RNase: design and engineering of Tat-RNase H that specifically recognizes and cleaves HIV-1 RNA in vitro.A high affinity binding site for the HIV-1 nucleocapsid protein.Co-packaging of sense and antisense RNAs: a novel strategy for blocking HIV-1 replication.Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter.Measuring cooperative Rev protein-protein interactions on Rev responsive RNA by fluorescence resonance energy transfer.Clinical use of quantitative molecular methods in studying human immunodeficiency virus type 1 infection.Inhibition of clinical human immunodeficiency virus (HIV) type 1 isolates in primary CD4+ T lymphocytes by retroviral vectors expressing anti-HIV genes.High-resolution mapping of the human T-cell leukemia virus type 1 Rex-binding element by in vitro selection.RNA aptamers selected to bind human immunodeficiency virus type 1 Rev in vitro are Rev responsive in vivoTransduction of human CD34+ hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits human immunodeficiency virus type 1 replication in myelomonocytic cells produced in long-term cultureIsolation of a nuclease-resistant decoy RNA that selectively blocks autoantibody binding to insulin receptors on human lymphocytes.Molding a peptide into an RNA site by in vivo peptide evolution.HIV/AIDS eradicationNovel cell and gene therapies for HIV.Comparative analyses of intracellularly expressed antisense RNAs as inhibitors of human immunodeficiency virus type 1 replicationAnti-Rex aptamers as mimics of the Rex-binding element.Interaction of human immunodeficiency virus-derived vectors with wild-type virus in transduced cells.Potent inhibition of human immunodeficiency virus type 1 replication by template analog reverse transcriptase inhibitors derived by SELEX (systematic evolution of ligands by exponential enrichment).Suppression of simian immunodeficiency virus replication by human immunodeficiency virus type 1 trans-dominant negative rev mutants.Intracellular expression of RNA transcripts complementary to the human immunodeficiency virus type 1 gag gene inhibits viral replication in human CD4+ lymphocytes.The Rev protein is able to transport to the cytoplasm small nucleolar RNAs containing a Rev binding element.Prospects for Foamy Viral Vector Anti-HIV Gene Therapy.CRISPR/Cas9 system targeting regulatory genes of HIV-1 inhibits viral replication in infected T-cell cultures.
P2860
Q24683706-73D1C1C2-79B3-4C8B-8F7F-20ABD48664F4Q28379462-9B751206-7E24-468B-A614-9C835F9BB302Q28472824-641399BF-2415-42E0-82BD-A7925FB95B9DQ33648134-0F23E8AD-BB37-4871-B6DA-DFFFF8F42F95Q33992464-2871BC2D-C307-488D-8046-CF761CFE1D6EQ34595695-A52CD277-CF79-43AB-9944-A4AEA51A0BCEQ34626657-59B01983-7A7E-4408-B8C3-B18D04847726Q34669645-232641F1-206C-4AF7-A779-C30A1346C7CDQ34757765-B5020039-F9A9-479D-A2BE-FFF0F2392ED1Q35079170-333170E7-2BDD-49D1-9A2A-8B7368BB6271Q35369891-CE4B2BC7-6FA7-46B5-BFE8-DB84A2050A51Q35840768-E2858C62-5743-4330-BE2D-0661B6402272Q35851865-D7864BFF-A522-4889-AC57-F9D1BA98448FQ35853408-832B68B3-2ED1-4C48-B772-02BDDEDAF261Q35863619-C0BFEBF1-4A94-48F2-BB1B-42F8A8880553Q36367219-97B7349A-C61D-4201-AE51-F3614C7EBF1DQ36625534-CD5585C0-64DF-4E35-AB47-DB16F216A787Q37021788-713E2502-416C-4024-A07D-EFE9A507FFD6Q38048762-A883B010-E317-46DA-8310-5F2EB812AC3EQ39577700-237365E6-6E21-41C7-9F0C-1BD5C6ADB596Q39594158-CDCCE850-8C3A-473C-AEC4-E0E574B89709Q39595638-E87111C9-840F-4423-8144-6DB1DCECD495Q39683830-5FF65545-A5C8-42B5-A61F-F47EA6CCC7DEQ39871345-E4C124D3-3558-4BA3-9D46-441396B7CA4CQ39877337-73309E56-CEBC-474D-B01E-83823894C08FQ40935808-1D4F4EAE-2D91-48F2-90B4-DBA9F7D24F58Q50878341-A5050516-C0CD-4FE5-8D24-763F901A6419Q54941488-B008735F-11BE-4861-810C-95234AD682A2
P2860
Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Inhibition of human immunodefi ...... de minimal Rev-binding domain.
@ast
Inhibition of human immunodefi ...... de minimal Rev-binding domain.
@en
type
label
Inhibition of human immunodefi ...... de minimal Rev-binding domain.
@ast
Inhibition of human immunodefi ...... de minimal Rev-binding domain.
@en
prefLabel
Inhibition of human immunodefi ...... de minimal Rev-binding domain.
@ast
Inhibition of human immunodefi ...... de minimal Rev-binding domain.
@en
P2093
P2860
P1433
P1476
Inhibition of human immunodefi ...... ide minimal Rev-binding domain
@en
P2093
P2860
P304
P407
P577
1994-12-01T00:00:00Z